Evidence map›Paper›PMID 39831041›Full record

ArticleRSC advances2025

Application of MMP-2-responsive

Wei Li, Yan Wang, Hongkun Miao, Maohui Yan, Chen Liu, Yu Wang, Jianjun Zhang, Zhiguang Fu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei LiCollege of Chemical Engineering, Beijing University of Chemical Technology Beijing 100029 China zhangjj@mail.buct.edu.cn.ORCID https://orcid.org/0000-0003-3018-4763
Yan WangDepartment of Internal Neurology 309 Hospital of PLA Beijing 100091 China.
Hongkun MiaoDepartment of Oncology, Air Force Medical Center, PLA Beijing 100142 China wangyufmmu@163.com.
Maohui YanDepartment of Radiotherapy, Air Force Medical Center, The Fourth Military Medical University, PLA No. 30 Fucheng Road, Haidian District Beijing 100142 China xiaochuan8668@126.com.
Chen LiuDepartment of Radiotherapy, Air Force Medical Center, The Fourth Military Medical University, PLA No. 30 Fucheng Road, Haidian District Beijing 100142 China xiaochuan8668@126.com.
Yu WangDepartment of Oncology, Air Force Medical Center, PLA Beijing 100142 China wangyufmmu@163.com.
Jianjun ZhangCollege of Chemical Engineering, Beijing University of Chemical Technology Beijing 100029 China zhangjj@mail.buct.edu.cn.ORCID https://orcid.org/0000-0002-3378-6113
Zhiguang FuDepartment of Radiotherapy, Air Force Medical Center, The Fourth Military Medical University, PLA No. 30 Fucheng Road, Haidian District Beijing 100142 China xiaochuan8668@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral squamous cell carcinoma is one of the most common types of cancer. Surgical resection is one of the most important treatments at present. However, patients often suffer from regional recurrence after surgery. Therefore, new strategies for combination therapy need to be investigated. This work identified a smart injectable hydrogel system co-delivering DOX and sunitinib nanoparticles. The nano drugs are continuously released from the hydrogels and effectively taken up by cells. The nano drugs in the hydrogel can inhibit tumor cell viability and induce cancer cell apoptosis

Identifiers

PMID39831041
PMCPMC11740019

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.